XTALPI (02228) saw an intraday surge of nearly 5%. As of the time of writing, the stock was up 3.88%, trading at HK$13.4, with a turnover of HK$596 million. Recently, LaiMang Bio, an enterprise incubated by XTALPI, delivered a presentation at the 44th J.P. Morgan Healthcare Conference, showcasing the latest results from its Investigator-Initiated Trial (IIT) for an ultra-low-dose CAR-T therapy to global investors. With research and development support from XTALPI, LaiMang Bio has developed multiple R&D pipelines based on its AI + immunometabolic reprogramming platform. Notably, its metabolism-enhanced CD19 CAR-T therapy, administered at an ultra-low dose as little as one-thousandth (1‰) of the conventional CAR-T therapeutic dose, has achieved complete remission (100% CR) and hospital discharge in multiple patients with systemic lupus erythematosus, demonstrating the potential for future "outpatient-style" CAR-T treatment. Concurrently, this therapy has already helped dozens of patients with relapsed/refractory leukemia/lymphoma achieve CR, and several IIT clinical trials in the field of solid tumors are either underway or set to commence soon. It is worth highlighting that XTALPI collaborated with LaiMang Bio to develop the META 10-AI platform, which integrates XTALPI's AI algorithms with high-throughput screening experiments to optimize the design of the core metabolism-enhancing factors used in the metabolism-enhanced CAR-T therapy, resulting in a several-hundred-fold improvement in affinity. The relevant results have now been submitted for a Chinese patent and are being applied in the development of metabolism-enhanced CAR-T pipelines targeting solid tumors, significantly enhancing the anti-exhaustion capability of CAR-T cells within the immunosuppressive microenvironment of solid tumors.